Physician profile
John D Flaugher
NPI 1558700567
$5,221.04
in general payments reported to CMS, 2019-2025
45 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,265 · 2020: $138 · 2021: $12.41 · 2022: $674 · 2023: $984 · 2024: $1,045 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,132.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $675.78 | 2019-2025 | |
| Novo Nordisk INC | $643.70 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $470.20 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $444.24 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $314.51 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $301.92 | 2019-2020 | |
| Abbott Laboratories | $285.08 | 2022-2025 | Freestyle Libre 3, Freestyle Libre |
| Amgen INC. | $236.10 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.32 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Medtronic, INC. | $150.46 | 2022-2025 | Interstim, Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $144.82 | 2019-2025 | |
| Abbvie INC. | $105.73 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.97 | 2022-2024 | |
| Astellas Pharma US INC | $87.22 | 2023-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $79.67 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Flaugher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.